89Zr-Trastuzumab-PET, Rapid Autopsies, and Patient Derived Xenografts to Determine the Extent of Clonal Evolution in Treatment Refractory HER2+ Gastric Cancer

Abstract

Trastuzumab, an FDA approved monoclonal antibody that binds to the extracellular domain of HER2, is the standard of care for these patients. However, after an initial response secondary resistance invariably ensues. The molecular basis of therapeutic resistance in HER2-positive EG cancer remains unknown and, until now, no other HER2-directed therapy has shown clinical efficacy in patients with trastuzumab refractory EG cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2019
Accession Number
AD1105402

Entities

People

  • Jason S. Lewis

Organizations

  • Memorial Sloan Kettering Cancer Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Breast Cancer
  • Cancer
  • Cell Line
  • Cell Physiological Processes
  • Cells
  • Chemotherapy
  • Data Analysis
  • Department Of Defense
  • Disease Attributes
  • Maryland
  • Mass Spectrometry
  • Mass Spectroscopy
  • Medical Personnel
  • Metastasis
  • Neoplasms
  • Oncology
  • Personal Information Managers
  • Professional Development
  • Proteins
  • Resistance
  • Spectrometry
  • Spectroscopy
  • Standards
  • Therapy
  • Tissues
  • X-Ray Computed Tomography
  • Xenografts

Readers

  • Oncology